ZURA
Zura Bio Ltd
NASDAQ · Healthcare · Biotechnology · US
$4.02
+0.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 65.9M | 42.1M | 24.4M | 44.0M | 23.7M |
| SG&A Expense | 36.1M | 33.2M | 30.8M | 18.6M | 3.5M |
| General & Admin Expense | 36.1M | 33.2M | 30.8M | 18.6M | 3.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 102.0M | 75.2M | 55.2M | 62.6M | 27.2M |
| Cost and Expenses | 102.0M | 75.2M | 55.2M | 62.6M | 27.2M |
| Operating Income (EBIT) | (102.0M) | (75.2M) | (55.2M) | (62.6M) | (27.2M) |
| Non-Operating | |||||
| Interest Income | 6.3M | 6.3M | 8.0M | 2.2M | 570.00 |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 6.3M | 6.3M | 8.0M | 2.2M | 570.00 |
| Other Non-Op Income/Expense | 7.2M | 6.6M | 2.8M | 2.1M | (171.0K) |
| Non-Operating Income (excl Interest) | (7.2M) | (6.6M) | (2.8M) | (2.1M) | 171.0K |
| EBT (Pre-Tax Income) | (94.8M) | (68.7M) | (52.4M) | (60.6M) | (27.3M) |
| Income Tax Expense | (1.3M) | — | — | — | — |
| Bottom Line | |||||
| Net Income | (93.5M) | (68.7M) | (52.4M) | (60.4M) | (25.7M) |
| Earnings from Cont. Ops | (93.5M) | (68.7M) | (52.4M) | (60.6M) | (27.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (122.2M) | (99.4M) | (45.4M) | (69.2M) | (32.4M) |
| Per Share | |||||
| Basic EPS | ($1.12) | ($1.06) | ($0.60) | ($2.09) | ($1.88) |
| Diluted EPS | ($1.12) | ($1.06) | ($0.60) | ($2.09) | ($1.88) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 127.7M | 94.2M | 75.1M | 33.1M | 17.3M |
| Diluted Shares Outstanding | 127.7M | 94.2M | 75.1M | 33.1M | 17.3M |
| Profitability Metrics | |||||
| EBITDA | (94.8M) | (68.6M) | (52.4M) | (60.6M) | (27.3M) |
| D&A | 67.0K | 49.0K | 9.0K | — | — |
| EBIT | (94.8M) | (68.7M) | (52.4M) | (60.6M) | (27.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026